Icon	Function
💬	A pop-up explanation appears when you mouse-over the text beside this icon. Also, an explanation window appears when you click this icon.
	The links beside this icon are links to external sites.
	Clicking this icon sorts the table by the item with this icon (Numerical or alphabetical order). Each click toggles between ascending and descending order.
	A text longer than 100 characters is fully displayed or collapsed.
	The contents of the displayed table are downloaded as a file named "table.csv".

DR info

Clinical trials : 7 / Drugs : 10 - (DrugBank : 3) / Drug target gene : 1 - Drug target pathways : 5

Drugs, Primary sponsors and Trial info (Enrollment year, Phase, Trial ID, Countries)

Fecal microbiota transplantation
   Jinling Hospital, China
      2014   -   NCT02731183   China
PLA-PRU-PLA-PRU
   Movetis
      2008   Phase 2   NCT00793247   United Kingdom
PLA-PRU-PRU-PLA
   Movetis
      2008   Phase 2   NCT00793247   United Kingdom
PRU-PLA-PLA-PRU
   Movetis
      2008   Phase 2   NCT00793247   United Kingdom
PRU-PLA-PRU-PLA
   Movetis
      2008   Phase 2   NCT00793247   United Kingdom
Rifaximin
   Ohkubo Hidenori
      2019   Phase 2   JPRN-jRCT2031190137   -
Rifaximin oral tablet
   Yokohama City University
      2019   Phase 2   NCT04118699   Japan
Sequential fecal microbiota transplant combined with small intestinal fluid transplant
   Shanghai 10th People's Hospital
      2018   -   NCT06020365   China
THRX-199687 hydrochloride
   ALFASIGMA S.P.A.
      2022   Phase 2   EUCTR2021-000854-24-BE   Belgium;Italy;Spain
      2021   Phase 2   EUCTR2021-000854-24-IT   Belgium;Italy;Spain
Velusetrag
   ALFASIGMA S.P.A.
      2022   Phase 2   EUCTR2021-000854-24-BE   Belgium;Italy;Spain
      2021   Phase 2   EUCTR2021-000854-24-IT   Belgium;Italy;Spain